126 related articles for article (PubMed ID: 35809536)
1. Corrigendum to "Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer" [Eur. J. Med. Chem. 238 (2022) 1-20/114484].
Cui H; Hu Z; Yang K; Huang J; Wu Y; Chen Q; Wei R; Wang P; Wang H; Li H; Chen Y; Lu T; Yao Y; Zhu Y
Eur J Med Chem; 2022 Oct; 240():114568. PubMed ID: 35809536
[No Abstract] [Full Text] [Related]
2. Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
Cui H; Hu Z; Yang K; Huang J; Wu Y; Chen Q; Wei R; Wang P; Wang H; Li H; Chen Y; Lu T; Yao Y; Zhu Y
Eur J Med Chem; 2022 Aug; 238():114484. PubMed ID: 35649291
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to "Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response" [Eur J Med Chem. 192 2020 112158].
Wu WC; Liu YM; Lin MH; Liao YH; Lai MJ; Chuang HY; Hung TY; Chen CH; Liou JP
Eur J Med Chem; 2020 Jun; 196():112329. PubMed ID: 32311605
[No Abstract] [Full Text] [Related]
4. Corrigendum to "Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer" [Eur. J. Med. Chem. 259 (2023) 115703/5].
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2024 Mar; 268():116230. PubMed ID: 38368135
[No Abstract] [Full Text] [Related]
5. Corrigendum to "N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression"[Eur. J. Med. Chem. 2020 Jan 1;185:111725].
Mehndiratta S; Lin MH; Wu YW; Chen CH; Wu TY; Chuang KH; Chao MW; Chen YY; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Aug; 199():112406. PubMed ID: 32408215
[No Abstract] [Full Text] [Related]
6. Corrigendum to "A fluorine scan on the Zn
Zhang B; Liu J; Gao D; Yu X; Wang J; Lei X
Eur J Med Chem; 2020 Jul; 198():112340. PubMed ID: 32371332
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Design and synthesis of novel artemisinin hybrids with potent activities against human colorectal cancer cells in vitro and in vivo" [Eur. J. Med. Chem. 182 (2019) 111665].
Wang LL; Kong L; Liu H; Zhang Y; Zhang L; Liu X; Yuan F; Li Y; Zuo Z
Eur J Med Chem; 2020 May; 194():112256. PubMed ID: 32220686
[No Abstract] [Full Text] [Related]
8. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
9. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum to "Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors" [Eur. J. Med. Chem. 197 (2020) 112308].
Shuai W; Li X; Li W; Xu F; Lu L; Yao H; Yang L; Zhu H; Xu S; Zhu Z; Xu J
Eur J Med Chem; 2020 Aug; 200():112464. PubMed ID: 32512484
[No Abstract] [Full Text] [Related]
11. Corrigendum to "Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors" [Eur. J. Med. Chem. 180 (2019) 171e190].
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2020 Jan; 186():111899. PubMed ID: 31787358
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis" [Eur. J. Med. Chem 209 (2021) 112942].
Faraji A; Oghabi Bakhshaiesh T; Hasanvand Z; Motahari R; Nazeri E; Boshagh MA; Firoozpour L; Mehrabi H; Khalaj A; Esmaeili R; Foroumadi A
Eur J Med Chem; 2021 Mar; 214():113228. PubMed ID: 33550180
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Synthesis and evaluation of 2,5-furan, 2,5-thiophene and 3,4-thiophene-based derivatives as CXCR4 inhibitors" [Eur. J. Med. Chem. 181 (2019) 111562].
Gaines T; Garcia F; Virani S; Liang Z; Yoon Y; Oum YH; Shim H; Mooring SR
Eur J Med Chem; 2023 Dec; 261():115753. PubMed ID: 37634992
[No Abstract] [Full Text] [Related]
14. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
[TBL] [Abstract][Full Text] [Related]
15. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity.
Jin ZZ; Wang W; Fang DL; Jin YJ
Biochem Biophys Res Commun; 2016 Sep; 478(4):1515-20. PubMed ID: 27565731
[TBL] [Abstract][Full Text] [Related]
17. Corrigendum to "Design, synthesis and biological evaluation of carbamate derivatives incorporating multifunctional carrier scaffolds as pseudo-irreversible cholinesterase inhibitors for the treatment of Alzheimer's disease" [Eur. J. Med. Chem. 265 (2024) 116071].
Liu Y; Ma C; Li Y; Li M; Cui T; Zhao X; Li Z; Jia H; Wang H; Xiu X; Hu D; Zhang R; Wang N; Liu P; Yang H; Cheng M
Eur J Med Chem; 2024 Mar; 267():116169. PubMed ID: 38290915
[No Abstract] [Full Text] [Related]
18. Corrigendum to: Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib [Eur. J. Med. Chem. 172 (2019) 143-153].
Poratti M; Marzaro G
Eur J Med Chem; 2020 Jun; 195():112272. PubMed ID: 32251743
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia" [Eur. J. Med. Chem. 221 (2021) 113522].
Ge H; Zhang W; Yuan K; Xue H; Cheng H; Chen W; Xie Y; Zhang J; Xu X; Yang P
Eur J Med Chem; 2022 Jan; 228():114041. PubMed ID: 34902733
[No Abstract] [Full Text] [Related]
20. Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].
Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
Eur J Med Chem; 2023 Apr; 252():115295. PubMed ID: 36989810
[No Abstract] [Full Text] [Related]
[Next] [New Search]
